News
![Novo leads $100m financing for Alzheimer's player Asceneuron](/sites/default/files/styles/x_large/public/2024-07/mii-luthman-tangled-rope-unsplash.jpg?itok=JbB3Cqf-)
Novo leads $100m financing for Alzheimer's player Asceneuron
Novo Nordisk's parent company, Novo Holdings, has led a $100 million third-round financing for Swiss biotech Asceneuron, which is developing a non-amyloid therapy for Alzheimer's disease.